{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-042365","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2026-06-11T11:04:42+00:00","discovered_at":"2026-06-11T11:10:00.215702+00:00","generated_at":"2026-06-11T11:10:24.251832+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"C4T Phase 1 cemsidomide in RRMM shows 53% ORR at RP2D, MRD negativity, well-tolerated","bullets":["53% ORR at 100 µg RP2D; 36% ORR across all doses (73 patients, median 7 prior lines).","MRD negativity achieved in two patients at RP2D (sCR and CR); responses deepened over time.","Median PFS 3.9 months (95% CI 3.2–5.6); median DOR 7.9 months (95% CI 3.0–NE).","No treatment discontinuations related to cemsidomide; manageable neutropenia (58% Grade 3/4).","ORR consistent across subgroups: prior CAR-T/TCE 53% at RP2D; prior BCMA 47% at RP2D."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-042365","json":"https://secwatch.observer/filing/0001628280-26-042365.json","markdown":"https://secwatch.observer/filing/0001628280-26-042365.md","text":"https://secwatch.observer/filing/0001628280-26-042365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026042365/0001628280-26-042365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026042365/cccc-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:10:24.251832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}